Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Julie Mchugh Sells 21,571 Shares

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Director Julie Mchugh sold 21,571 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total value of $80,459.83. Following the transaction, the director directly owned 250,749 shares in the company, valued at $935,293.77. This trade represents a 7.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Ironwood Pharmaceuticals Trading Down 3.8%

Shares of NASDAQ:IRWD opened at $3.52 on Thursday. The stock has a market capitalization of $573.97 million, a P/E ratio of 5.87 and a beta of 0.25. Ironwood Pharmaceuticals, Inc. has a 12-month low of $0.62 and a 12-month high of $5.78. The stock’s 50-day moving average price is $3.83 and its 200-day moving average price is $3.88.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The business had revenue of $106.51 million during the quarter, compared to the consensus estimate of $92.11 million. Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%. As a group, research analysts predict that Ironwood Pharmaceuticals, Inc. will post 1.04 EPS for the current year.

Analyst Ratings Changes

Several brokerages have commented on IRWD. Weiss Ratings restated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, April 27th. Jefferies Financial Group restated a “hold” rating and issued a $3.70 price objective on shares of Ironwood Pharmaceuticals in a report on Thursday, February 26th. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Finally, Citizens Jmp lifted their target price on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $6.23.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IRWD. Segall Bryant & Hamill LLC purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter worth $976,000. Bull Harbor Capital LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter valued at about $48,000. EverSource Wealth Advisors LLC raised its position in shares of Ironwood Pharmaceuticals by 48.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 20,336 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 6,656 shares in the last quarter. Quantinno Capital Management LP grew its holdings in Ironwood Pharmaceuticals by 9.1% during the 1st quarter. Quantinno Capital Management LP now owns 129,703 shares of the biotechnology company’s stock valued at $455,000 after purchasing an additional 10,810 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp grew its holdings in Ironwood Pharmaceuticals by 5.2% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 226,310 shares of the biotechnology company’s stock valued at $794,000 after purchasing an additional 11,200 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.